|
1
|
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
|
N Engl J Med
|
2008
|
27.35
|
|
2
|
Cetuximab for the treatment of colorectal cancer.
|
N Engl J Med
|
2007
|
13.39
|
|
3
|
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
|
N Engl J Med
|
2003
|
12.17
|
|
4
|
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
|
JAMA
|
2010
|
6.65
|
|
5
|
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
|
J Clin Oncol
|
2005
|
6.38
|
|
6
|
Advanced pancreatic carcinoma: current treatment and future challenges.
|
Nat Rev Clin Oncol
|
2010
|
5.07
|
|
7
|
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
|
J Natl Cancer Inst
|
2011
|
4.08
|
|
8
|
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
|
J Clin Oncol
|
2009
|
3.61
|
|
9
|
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.
|
J Clin Oncol
|
2008
|
3.49
|
|
10
|
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
|
Oncologist
|
2007
|
3.42
|
|
11
|
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
|
Lancet Oncol
|
2012
|
3.02
|
|
12
|
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
|
JAMA
|
2012
|
2.88
|
|
13
|
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
|
J Clin Oncol
|
2005
|
2.52
|
|
14
|
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
|
J Natl Cancer Inst
|
2009
|
2.16
|
|
15
|
Randomized phase II trials: inevitable or inadvisable?
|
J Clin Oncol
|
2010
|
2.02
|
|
16
|
Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.
|
Eur Urol
|
2010
|
1.67
|
|
17
|
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.
|
Clin Cancer Res
|
2006
|
1.63
|
|
18
|
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
|
Clin Cancer Res
|
2006
|
1.58
|
|
19
|
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
|
J Natl Cancer Inst
|
2013
|
1.54
|
|
20
|
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer.
|
Cancer
|
2006
|
1.50
|
|
21
|
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
|
Cancer
|
2010
|
1.50
|
|
22
|
Alternate endpoints for screening phase II studies.
|
Clin Cancer Res
|
2009
|
1.47
|
|
23
|
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
|
J Clin Oncol
|
2009
|
1.40
|
|
24
|
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
|
J Clin Oncol
|
2013
|
1.39
|
|
25
|
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy.
|
J Clin Oncol
|
2011
|
1.29
|
|
26
|
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.
|
Am J Clin Oncol
|
2006
|
1.29
|
|
27
|
Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
|
J Clin Oncol
|
2010
|
1.23
|
|
28
|
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
|
Clin Cancer Res
|
2013
|
1.22
|
|
29
|
Sorafenib for metastatic renal cancer: the Princess Margaret experience.
|
Am J Clin Oncol
|
2008
|
1.22
|
|
30
|
A review of erlotinib and its clinical use.
|
Expert Opin Pharmacother
|
2006
|
1.18
|
|
31
|
A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.
|
Cancer
|
2013
|
1.16
|
|
32
|
Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital.
|
Am J Clin Oncol
|
2008
|
1.11
|
|
33
|
Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer.
|
J Clin Oncol
|
2010
|
1.05
|
|
34
|
Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
|
Clin Cancer Res
|
2012
|
1.02
|
|
35
|
The role of systemic chemotherapy in the management of muscle-invasive bladder cancer.
|
Lancet Oncol
|
2002
|
1.01
|
|
36
|
Epidermal growth factor receptor expression in anal canal carcinoma.
|
Am J Clin Pathol
|
2005
|
1.01
|
|
37
|
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
|
Invest New Drugs
|
2013
|
0.99
|
|
38
|
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
|
Am J Clin Oncol
|
2010
|
0.97
|
|
39
|
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.
|
Oncologist
|
2014
|
0.96
|
|
40
|
Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres.
|
Can J Urol
|
2005
|
0.95
|
|
41
|
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2005
|
0.93
|
|
42
|
A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.
|
Eur J Cancer
|
2005
|
0.93
|
|
43
|
A Phase II study of oxaliplatin in urothelial cancer.
|
Urol Oncol
|
2005
|
0.92
|
|
44
|
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
|
Invest New Drugs
|
2010
|
0.92
|
|
45
|
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
|
J Clin Oncol
|
2004
|
0.91
|
|
46
|
Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer.
|
J Clin Oncol
|
2008
|
0.91
|
|
47
|
Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
|
Future Oncol
|
2007
|
0.89
|
|
48
|
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
|
Invest New Drugs
|
2010
|
0.89
|
|
49
|
Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks.
|
Invest New Drugs
|
2003
|
0.89
|
|
50
|
Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors.
|
Acta Oncol
|
2009
|
0.87
|
|
51
|
A Phase 2 study of perifosine in advanced or metastatic breast cancer.
|
Breast Cancer Res Treat
|
2007
|
0.87
|
|
52
|
Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?
|
J Clin Oncol
|
2007
|
0.86
|
|
53
|
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
|
Invest New Drugs
|
2006
|
0.85
|
|
54
|
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
|
Invest New Drugs
|
2013
|
0.84
|
|
55
|
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
|
Invest New Drugs
|
2011
|
0.84
|
|
56
|
A case of small bowel obstruction due to intraluminal metastases from metastatic renal cell cancer.
|
Oncologist
|
2008
|
0.83
|
|
57
|
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
|
Cancer Chemother Pharmacol
|
2010
|
0.83
|
|
58
|
Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial.
|
Support Care Cancer
|
2002
|
0.83
|
|
59
|
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.
|
Invest New Drugs
|
2009
|
0.82
|
|
60
|
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.
|
Urol Oncol
|
2005
|
0.82
|
|
61
|
Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days.
|
Invest New Drugs
|
2004
|
0.82
|
|
62
|
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
|
J Thorac Oncol
|
2009
|
0.80
|
|
63
|
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
|
Clin Cancer Res
|
2006
|
0.80
|
|
64
|
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2012
|
0.80
|
|
65
|
Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2005
|
0.80
|
|
66
|
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
|
Invest New Drugs
|
2011
|
0.77
|
|
67
|
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.
|
Cancer
|
2013
|
0.76
|
|
68
|
Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia.
|
J Clin Oncol
|
2008
|
0.76
|
|
69
|
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
|
Cancer Chemother Pharmacol
|
2005
|
0.75
|
|
70
|
Depression and use of health care services in patients with advanced cancer.
|
Can Fam Physician
|
2013
|
0.75
|
|
71
|
Surgical oncology: Is PBD suitable for resectable pancreatic cancer?
|
Nat Rev Clin Oncol
|
2010
|
0.75
|
|
72
|
Outcome and toxicity of postoperative short course adjuvant radiation and chemotherapy following resection of adenocarcinoma of the rectum.
|
Acta Oncol
|
2004
|
0.75
|
|
73
|
Eyelid metastasis from mediastinal teratoma with malignant transformation.
|
Acta Oncol
|
2007
|
0.75
|
|
74
|
Targeting metastatic prostate cancer: the search for innovative systemic therapies.
|
Oncology (Williston Park)
|
2006
|
0.75
|
|
75
|
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.
|
Clin Genitourin Cancer
|
2013
|
0.75
|
|
76
|
Novel targets in prostate cancer.
|
Expert Opin Ther Targets
|
2006
|
0.75
|